+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

COPD and Asthma Devices Market by Product Type, Indication and Distribution Channel: Global Opportunity Analysis and Industry Forecast 2020-2027

  • ID: 5134124
  • Report
  • June 2020
  • Region: Global
  • 276 pages
  • Allied Analytics LLP

FEATURED COMPANIES

  • 3M COMPANY
  • Aerogen Inc
  • AstraZeneca PLC
  • Baxter International Inc
  • GF Health Products
  • GlaxoSmithKline Plc
The global COPD and asthma devices market is expected to reach $51,628.58 million by 2027, registering a CAGR of 4.30% during 2020-2027. Chronic obstructive pulmonary disease (COPD) and asthma devices, also known as pulmonary drug delivery devices, are used as a permanent treatment or rescue therapy for respiratory diseases and other related ailments. It is the most advanced mode of drug administration in which the drug is directly delivered to the lungs to provide a systemic effect. COPD and asthma have significant shares in the global respiratory diseases market. According to the Global Health Organization (WHO), in 2016, around 251 million cases of COPD were estimated globally. Thus, a variety of drug-delivery protocols, such as oral and parenteral delivery, are developed for the treatment of COPD and asthma. However, the pulmonary drug delivery system is the most effective treatment option as compared to the other conventional methods.

The major factors that drive market growth are an increase in concerns of respiratory diseases, such as asthma and emphysema, and a rise in incidences of respiratory diseases caused due to cigarette consumption. Furthermore, an increase in healthcare expenditure, growth in use of automation in the healthcare industry, and rapid adoption of advanced medical solutions also boost market growth. Currently, most of healthcare practitioners and pulmonary diseases specialists prefer a combination of a drug and a device, for instance, inhaler and nebulizer, owing to its fast and effective outcome. However, the factors such as high cost associated with nebulizers, side effects occurring due to excessive dosage, and lack of awareness regarding drug inhalation are expected to restrain the growth of the market. On the contrary, introduction of smart inhaler drives the opportunity for the growth of COPD and asthma devices market in near future.

The global COPD and asthma devices market is segmented on the basis of product type, indication, distributional channel, and region. Based on the device type, the market is segmented into inhalers and nebulizers. Furthermore, the inhalers segment includes dry powder inhalers (DPIs), metered dose inhalers (MDIs), and soft mist inhalers (SMIs). However, the nebulizers segment includes compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers. Based on indication, the market is divided into asthma and COPD. Based on the distribution channel, it is segregated into retail pharmacies, online pharmacies, and hospitals. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. These regions are further analyzed on the basis of the respective countries.

The leading players profiled in this report include Aerogen, Inc., AstraZeneca PLC, Baxter International Inc., Boehringer Ingelheim International GmbH, 3M COMPANY, GF Health Products, GlaxoSmithKline Plc, Koninklijke Philips N.V., Novartis AG, PARI Medical Holding GMBH, and Smith’s Group Plc.

KEY BENEFITS FOR STAKEHOLDERS
  • This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
Key Market Segments

By Product Type
  • Inhalers
  • Drug Powder Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
  • Soft Mist Inhalers (SMIs)
  • Nebulizers
  • Compressor Nebulizers
  • Ultrasonic Nebulizers
  • Mesh Nebulizers
By Indication
  • Asthma
  • COPD
By Distribution Channel
  • Retail Pharmacies
  • Hospitals
  • Online Pharmacies
  • By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • Middle East
  • Saudi Arabia
  • Brazil
  • Argentina
  • Colombia
  • Turkey
  • Rest of LAMEA
List of key players profiled in the report
  • Aerogen, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • 3M COMPANY
  • GF Health Products
  • GlaxoSmithKline Plc
  • Koninklijke Philips N.V.
  • Novartis AG
  • PARI Medical Holding GMBH
  • Smith’s Group Plc.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
  • Lincare Holdings Inc
  • Allied Healthcare Products Inc
  • Sunovion Pharmaceuticals Inc
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3M COMPANY
  • Aerogen Inc
  • AstraZeneca PLC
  • Baxter International Inc
  • GF Health Products
  • GlaxoSmithKline Plc
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models

Chapter 2: Executive Summary
2.1. Key Findings of the Study:
2.2. CXO Perspective

Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.2.3. Top Winning Strategies, 2016-2018
3.3. Porter’sFive Forces Analysis
3.3.1. Moderate Bargaining Power of Buyers
3.3.2. Low Bargaining Power of Suppliers
3.3.3. Moderate Threat of Substitutes
3.3.4. Low Threat of New Entrants
3.3.5. Moderate Competitive Rivalry
3.4. Value Chain Analysis
3.5. Government Regulations
3.5.1. Copd Devices Regulations in Europe and in the U. S.
3.5.2. Copd Devices Regulations in Asia-Pacific
3.6. Clinical Trials
3.7. Patent Analysis
3.7.1. Patent Analysis by Region
3.7.2. U. S. Patent Analysis
3.7.3. Europe Patent Analysis
3.7.4. Japan Patent Analysis
3.8. Drivers
3.8.1. Daily Exposure to Environmental Pollution
3.8.2. Increase in Population Susceptible to Indoor Air Pollutants
3.8.3. Portability of the Drug Delivery Devices
3.8.4. Increasing Population of Active Smokers
3.8.5. Rising Government Initiatives
3.9. Restraints
3.9.1. Increase in Price Competition and Deterioration of Material Quality
3.9.2. Overall High Cost of Asthma Treatment is a Challenge for the Patients
3.9.3. Incompetent Reimbursement Support
3.10. Opportunities
3.10.1. Patent Expiration for Blockbuster Drugs
3.10.2. Smart Inhaler: Future Growth Driver

Chapter 4: Copd and Asthma Devices Market, by Product
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Inhalers
4.2.1. Market Size and Forecast
4.2.2. Market Share Analysis, by Country
4.2.3. Drug Powdered Inhalers (Dpis)
4.2.3.1. Key Market Trends and Opportunity
4.2.4. Metered Dose Inhalers (Mdis)
4.2.4.1. Key Market Trends and Opportunity
4.2.5. Soft Mist Inhalers
4.2.5.1. Key Market Trends and Opportunity
4.3. Nebulizers
4.3.1. Market Size and Forecast
4.3.2. Market Share Analysis, by Country
4.3.2.1. Compressor Nebulizers
4.3.2.2. Ultrasonic Nebulizers
4.3.2.3. Mesh Nebulizers

Chapter 5: Copd and Asthma Devices Market, by Indication
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Asthma
5.2.1. Market Size and Forecast
5.2.2. Market Share Analysis, by Country
5.3. Copd
5.3.1. Market Size and Forecast
5.3.2. Market Share Analysis, by Country

Chapter 6: Copd and Asthma Devices Market, by Distribution Channel
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Retail Pharmacies
6.2.1. Market Size and Forecast
6.2.2. Market Share Analysis, by Country
6.3. Hospitals
6.3.1. Market Size and Forecast
6.3.2. Market Share Analysis, by Country
6.4. Online Pharmacies
6.4.1. Market Size and Forecast
6.4.2. Market Share Analysis, by Country

Chapter 7: Copd & Asthma Device Market, by Region
7.1. Overview
7.1.1. Market Size and Forecast
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. North America Market Size and Forecast, by Country
7.2.3. North America Market Size and Forecast, by Product
7.2.4. North America Market Size and Forecast, by Indication
7.2.5. North America Market Size and Forecast, by Distribution Channel
7.2.5.1. U. S.
7.2.5.1.1. U. S. Market Size and Forecast, by Product
7.2.5.1.2. U. S. Market Size and Forecast, by Indication
7.2.5.1.3. U. S. Market Size and Forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Canada Market Size and Forecast, by Product
7.2.5.2.2. Canada Market Size and Forecast, by Indication
7.2.5.2.3. Canada Market Size and Forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Mexico Market Size and Forecast, by Product
7.2.5.3.2. Mexico Market Size and Forecast, by Indication
7.2.5.3.3. Mexico Market Size and Forecast, by Distribution Channel
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Europe Market Size and Forecast, by Country
7.3.3. Europe Market Size and Forecast, by Product
7.3.4. Europe Market Size and Forecast, by Indication
7.3.5. Europe Market Size and Forecast, by Distribution Channel
7.3.5.1. Germany
7.3.5.1.1. Germany Market Size and Forecast, by Product
7.3.5.1.2. Germany Market Size and Forecast, by Indication
7.3.5.1.3. Germany Market Size and Forecast, by Distribution Channel
7.3.5.2. UK
7.3.5.2.1. UK Market Size and Forecast, by Product
7.3.5.2.2. UK Market Size and Forecast, by Indication
7.3.5.2.3. UK Market Size and Forecast, by Distribution Channel
7.3.5.3. France
7.3.5.3.1. France Market Size and Forecast, by Product
7.3.5.3.2. France Market Size and Forecast, by Indication
7.3.5.3.3. France Market Size and Forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Italy Market Size and Forecast, by Product
7.3.5.4.2. Italy Market Size and Forecast, by Indication
7.3.5.4.3. Italy Market Size and Forecast, by Distribution Channel
7.3.5.5. Russia
7.3.5.5.1. Russia Market Size and Forecast, by Product
7.3.5.5.2. Russia Market Size and Forecast, by Indication
7.3.5.5.3. Russia Market Size and Forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Rest of Europe Market Size and Forecast, by Product
7.3.5.6.2. Rest of Europe Market Size and Forecast, by Indication
7.3.5.6.3. Rest of Europe Market Size and Forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Asia-Pacific Market Size and Forecast, by Country
7.4.3. Asia-Pacific Market Size and Forecast, by Product
7.4.4. Asia-Pacific Market Size and Forecast, by Indication
7.4.5. Asia-Pacific Market Size and Forecast, by Distribution Channel
7.4.5.1. Japan
7.4.5.1.1. Japan Market Size and Forecast, by Product
7.4.5.1.2. Japan Market Size and Forecast, by Indication
7.4.5.1.3. Japan Market Size and Forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. China Market Size and Forecast, by Product
7.4.5.2.2. China Market Size and Forecast, by Indication
7.4.5.2.3. China Market Size and Forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. India Market Size and Forecast, by Product
7.4.5.3.2. India Market Size and Forecast, by Indication
7.4.5.3.3. India Market Size and Forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Australia Market Size and Forecast, by Product
7.4.5.4.2. Australia Market Size and Forecast, by Indication
7.4.5.4.3. Australia Market Size and Forecast, by Distribution Channel
7.4.5.5. Rest of Asia-Pacific
7.4.5.5.1. Rest of Asia-Pacific Market Size and Forecast, by Product
7.4.5.5.2. Rest of Asia-Pacific Market Size and Forecast, by Indication
7.4.5.5.3. Rest of Asia-Pacific Market Size and Forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. LAMEA Market Size and Forecast, by Country
7.5.3. LAMEA Market Size and Forecast, by Product
7.5.4. LAMEA Market Size and Forecast, by Indication
7.5.5. LAMEA Market Size and Forecast, by Distribution Channel
7.5.5.1. Brazil
7.5.5.1.1. Brazil Market Size and Forecast, by Product
7.5.5.1.2. Brazil Market Size and Forecast, by Indication
7.5.5.1.3. Brazil Market Size and Forecast, by Distribution Channel
7.5.5.2. Argentina
7.5.5.2.1. Argentina Market Size and Forecast, by Product
7.5.5.2.2. Argentina Market Size and Forecast, by Indication
7.5.5.2.3. Argentina Market Size and Forecast, by Distribution Channel
7.5.5.3. Saudi Arabia
7.5.5.3.1. Saudi Arabia Market Size and Forecast, by Product
7.5.5.3.2. Saudi Arabia Market Size and Forecast, by Indication
7.5.5.3.3. Saudi Arabia Market Size and Forecast, by Distribution Channel
7.5.5.4. Colombia
7.5.5.4.1. Colombia Market Size and Forecast, by Product
7.5.5.4.2. Colombia Market Size and Forecast, by Indication
7.5.5.4.3. Colombia Market Size and Forecast, by Distribution Channel
7.5.5.5. Turkey
7.5.5.5.1. Turkey Market Size and Forecast, by Product
7.5.5.5.2. Turkey Market Size and Forecast, by Indication
7.5.5.5.3. Turkey Market Size and Forecast, by Distribution Channel
7.5.5.6. Rest of LAMEA
7.5.5.6.1. Rest of LAMEA Market Size and Forecast, by Product
7.5.5.6.2. Rest of LAMEA Market Size and Forecast, by Indication
7.5.5.6.3. Rest of LAMEA Market Size and Forecast, by Distribution Channel

Chapter 8: Company Profiles
8.1. Aerogen, Inc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Product Portfolio
8.2. Astrazeneca plc
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.2.6. Key Strategic Moves and Developments
8.3. Baxter International Inc.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.4. Boehringer Ingelheim International GmbH
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.5.3M Company
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves and Developments
8.6. Gf Health Products, Inc.
8.6.1. Company Overview
8.6.2. Product Portfolio
8.7. GlaxoSmithKline plc
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.7.6. Key Strategic Moves and Developments
8.8. Koninklijke Philips N. V. (Philips)
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves and Developments
8.9. Novartis AG
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.9.6. Key Strategic Moves and Developments
8.10. Pari Medical Holding GmbH
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Key Strategic Moves and Developments
8.11. Smith’S Group plc
8.11.1. Company Overview
8.11.2. Company Snapshot
8.11.3. Operating Business Segments
8.11.4. Product Portfolio
8.11.5. Business Performance
Note: Product cover images may vary from those shown
  • Aerogen Inc
  • AstraZeneca PLC
  • Baxter International Inc
  • Boehringer Ingelheim International GmbH
  • 3M COMPANY
  • GF Health Products
  • GlaxoSmithKline Plc
  • Koninklijke Philips NV
  • Novartis AG
  • PARI medical Holding GMBH
  • Smith’s Group Plc
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll